Aspire BioPharma, Inc. Cash Flow-to-Debt Ratio
Aspire BioPharma, Inc. cash flow-to-debt ratio. Aspire BioPharma, Inc. (ASBP) has a Cash Flow-to-Debt Ratio of -1.19x as of June 2026, meaning its operating cash flow of $-2.12 Million could theoretically repay -1% of its total liabilities ($1.78 Million) in one year. Check Aspire BioPharma, Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aspire BioPharma, Inc. (2021–2025)
Cash flow-to-debt ratio of Aspire BioPharma, Inc. from 2021 to 2025. Historical debt coverage capacity for Aspire BioPharma, Inc. across 5 annual periods. Check total reinvestment intensity of Aspire BioPharma, Inc. to assess the company's total reinvestment commitment from operating cash flow.
Aspire BioPharma, Inc. Cash Flow-to-Debt Ratio by Year (2021–2025)
Aspire BioPharma, Inc. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Aspire BioPharma, Inc.. For the full cash flow conversion analysis, see ASBP cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.64x | $-4.92 Million | $7.69 Million | ▼ -307.6% |
| 2024 | -0.16x | $-265.19K | $1.69 Million | ▲ +90.3% |
| 2023 | -1.62x | $-653.11K | $403.33K | ▼ -12495.6% |
| 2022 | -0.01x | $-142.91K | $11.12 Million | ▼ -1352.2% |
| 2021 | 0.00x | $-260.00 | $293.70K | — |